{"pmid":32423922,"title":"More advice on the use of ibuprofen for COVID-19.","text":["More advice on the use of ibuprofen for COVID-19.","Every month, DTB scans sources of information on treatments, disease management and other healthcare topics for key items to bring to our readers' attention and help them keep up to date. To do this, we produce succinct, contextualised summaries of the information concerned.","Drug Ther Bull","32423922"],"abstract":["Every month, DTB scans sources of information on treatments, disease management and other healthcare topics for key items to bring to our readers' attention and help them keep up to date. To do this, we produce succinct, contextualised summaries of the information concerned."],"journal":"Drug Ther Bull","date":"2020-05-20T11:00:00Z","year":2020,"_id":"32423922","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1136/dtb.2020.000032","keywords":["evidence-based medicine","health care quality, access, and evaluation"],"e_drugs":["Ibuprofen"],"topics":["Prevention"],"weight":1,"_version_":1667252838027231232,"score":9.490897,"similar":[{"pmid":32234728,"title":"EMA advice on the use of NSAIDs for Covid-19.","text":["EMA advice on the use of NSAIDs for Covid-19.","Every month, DTB scans sources of information on treatments, disease management and other healthcare topics for key items to bring to our readers' attention and help them keep up to date. To do this, we produce succinct, contextualised summaries of the information concerned.","Drug Ther Bull","32234728"],"abstract":["Every month, DTB scans sources of information on treatments, disease management and other healthcare topics for key items to bring to our readers' attention and help them keep up to date. To do this, we produce succinct, contextualised summaries of the information concerned."],"journal":"Drug Ther Bull","date":"2020-04-03T11:00:00Z","year":2020,"_id":"32234728","source":"PubMed","week":"202014|Mar 30 - Apr 05","doi":"10.1136/dtb.2020.000021","keywords":["health care quality, access, and evaluation","primary health care"],"topics":["Treatment"],"weight":1,"_version_":1666138490418495488,"score":521.90344},{"pmid":32295811,"title":"EMA advice on renin-angiotensin system medicines during covid-19 pandemic.","text":["EMA advice on renin-angiotensin system medicines during covid-19 pandemic.","Every month, DTB scans sources of information on treatments, disease management and other healthcare topics for key items to bring to our readers' attention and help them keep up to date. To do this, we produce succinct, contextualised summaries of the information concerned.","Drug Ther Bull","32295811"],"abstract":["Every month, DTB scans sources of information on treatments, disease management and other healthcare topics for key items to bring to our readers' attention and help them keep up to date. To do this, we produce succinct, contextualised summaries of the information concerned."],"journal":"Drug Ther Bull","date":"2020-04-17T11:00:00Z","year":2020,"_id":"32295811","source":"PubMed","week":"202016|Apr 13 - Apr 19","doi":"10.1136/dtb.2020.000026","keywords":["health care quality, access, and evaluation","primary health care"],"topics":["Prevention"],"weight":1,"_version_":1666138493316759553,"score":508.90198},{"pmid":32029004,"pmcid":"PMC7003341","title":"A rapid advice guideline for the diagnosis and treatment of 2019 novel coronavirus (2019-nCoV) infected pneumonia (standard version).","text":["A rapid advice guideline for the diagnosis and treatment of 2019 novel coronavirus (2019-nCoV) infected pneumonia (standard version).","In December 2019, a new type viral pneumonia cases occurred in Wuhan, Hubei Province; and then named \"2019 novel coronavirus (2019-nCoV)\" by the World Health Organization (WHO) on 12 January 2020. For it is a never been experienced respiratory disease before and with infection ability widely and quickly, it attracted the world's attention but without treatment and control manual. For the request from frontline clinicians and public health professionals of 2019-nCoV infected pneumonia management, an evidence-based guideline urgently needs to be developed. Therefore, we drafted this guideline according to the rapid advice guidelines methodology and general rules of WHO guideline development; we also added the first-hand management data of Zhongnan Hospital of Wuhan University. This guideline includes the guideline methodology, epidemiological characteristics, disease screening and population prevention, diagnosis, treatment and control (including traditional Chinese Medicine), nosocomial infection prevention and control, and disease nursing of the 2019-nCoV. Moreover, we also provide a whole process of a successful treatment case of the severe 2019-nCoV infected pneumonia and experience and lessons of hospital rescue for 2019-nCoV infections. This rapid advice guideline is suitable for the first frontline doctors and nurses, managers of hospitals and healthcare sections, community residents, public health persons, relevant researchers, and all person who are interested in the 2019-nCoV.","Mil Med Res","Jin, Ying-Hui","Cai, Lin","Cheng, Zhen-Shun","Cheng, Hong","Deng, Tong","Fan, Yi-Pin","Fang, Cheng","Huang, Di","Huang, Lu-Qi","Huang, Qiao","Han, Yong","Hu, Bo","Hu, Fen","Li, Bing-Hui","Li, Yi-Rong","Liang, Ke","Lin, Li-Kai","Luo, Li-Sha","Ma, Jing","Ma, Lin-Lu","Peng, Zhi-Yong","Pan, Yun-Bao","Pan, Zhen-Yu","Ren, Xue-Qun","Sun, Hui-Min","Wang, Ying","Wang, Yun-Yun","Weng, Hong","Wei, Chao-Jie","Wu, Dong-Fang","Xia, Jian","Xiong, Yong","Xu, Hai-Bo","Yao, Xiao-Mei","Yuan, Yu-Feng","Ye, Tai-Sheng","Zhang, Xiao-Chun","Zhang, Ying-Wen","Zhang, Yin-Gao","Zhang, Hua-Min","Zhao, Yan","Zhao, Ming-Juan","Zi, Hao","Zeng, Xian-Tao","Wang, Yong-Yan","Wang, Xing-Huan","32029004"],"abstract":["In December 2019, a new type viral pneumonia cases occurred in Wuhan, Hubei Province; and then named \"2019 novel coronavirus (2019-nCoV)\" by the World Health Organization (WHO) on 12 January 2020. For it is a never been experienced respiratory disease before and with infection ability widely and quickly, it attracted the world's attention but without treatment and control manual. For the request from frontline clinicians and public health professionals of 2019-nCoV infected pneumonia management, an evidence-based guideline urgently needs to be developed. Therefore, we drafted this guideline according to the rapid advice guidelines methodology and general rules of WHO guideline development; we also added the first-hand management data of Zhongnan Hospital of Wuhan University. This guideline includes the guideline methodology, epidemiological characteristics, disease screening and population prevention, diagnosis, treatment and control (including traditional Chinese Medicine), nosocomial infection prevention and control, and disease nursing of the 2019-nCoV. Moreover, we also provide a whole process of a successful treatment case of the severe 2019-nCoV infected pneumonia and experience and lessons of hospital rescue for 2019-nCoV infections. This rapid advice guideline is suitable for the first frontline doctors and nurses, managers of hospitals and healthcare sections, community residents, public health persons, relevant researchers, and all person who are interested in the 2019-nCoV."],"journal":"Mil Med Res","authors":["Jin, Ying-Hui","Cai, Lin","Cheng, Zhen-Shun","Cheng, Hong","Deng, Tong","Fan, Yi-Pin","Fang, Cheng","Huang, Di","Huang, Lu-Qi","Huang, Qiao","Han, Yong","Hu, Bo","Hu, Fen","Li, Bing-Hui","Li, Yi-Rong","Liang, Ke","Lin, Li-Kai","Luo, Li-Sha","Ma, Jing","Ma, Lin-Lu","Peng, Zhi-Yong","Pan, Yun-Bao","Pan, Zhen-Yu","Ren, Xue-Qun","Sun, Hui-Min","Wang, Ying","Wang, Yun-Yun","Weng, Hong","Wei, Chao-Jie","Wu, Dong-Fang","Xia, Jian","Xiong, Yong","Xu, Hai-Bo","Yao, Xiao-Mei","Yuan, Yu-Feng","Ye, Tai-Sheng","Zhang, Xiao-Chun","Zhang, Ying-Wen","Zhang, Yin-Gao","Zhang, Hua-Min","Zhao, Yan","Zhao, Ming-Juan","Zi, Hao","Zeng, Xian-Tao","Wang, Yong-Yan","Wang, Xing-Huan"],"date":"2020-02-08T11:00:00Z","year":2020,"_id":"32029004","source":"PubMed","week":"20206|Feb 03 - Feb 09","doi":"10.1186/s40779-020-0233-6","keywords":["2019 novel coronavirus","2019-ncov","clinical practice guideline","evidence-based medicine","infectious diseases","pneumonia","rapid advice guideline","respiratory disease"],"link_comment_in":"32245395","locations":["Wuhan","Hubei","Chinese"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Treatment","Diagnosis","Prevention","Mechanism"],"weight":1,"_version_":1666138490883014657,"score":82.154686},{"pmid":32255438,"title":"Evidence synthesis relevant to COVID-19: a protocol for multiple systematic reviews and overviews of systematic reviews.","text":["Evidence synthesis relevant to COVID-19: a protocol for multiple systematic reviews and overviews of systematic reviews.","Introduction: The evidence on COVID-19 is being produced at high speed, so it is challenging for decision-makers to keep up. It seems appropriate, then, to put into practice a novel approach able to provide the scientific community and other interested parties with quality evidence that is actionable, and rapidly and efficiently produced. Methods and analysis: We designed a protocol for multiple parallel systematic reviews and overviews of systematic reviews in line with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses Protocols (PRISMA-P). We will search for primary studies and systematic reviews that answer different questions related to COVID-19 using both a centralized repository (Epistemonikos database) and a manual search in MEDLINE/PubMed, EMBASE, and the Cochrane Central Register of Controlled Trials. We will also search for literature in several other sources. At least two researchers will independently undertake the selection of studies, data extraction, and assessment of the quality of the included studies. We will synthesize data for each question using meta-analysis, when possible, and we will prepare Summary of Findings tables according to the GRADE approach. All the evidence will be organized in an open platform (L.OVE - Living OVerview of Evidence) that will be continuously updated using artificial intelligence and a broad network of experts. Ethics and dissemination: No ethics approval is considered necessary. The results of these articles will be widely disseminated via peer-reviewed publications, social networks, and traditional media, and will be sent to relevant international organizations discussing this topic.","Medwave","Rada, Gabriel","Verdugo-Paiva, Francisca","Avila, Camila","Morel-Marambio, Macarena","Bravo-Jeria, Rocio","Pesce, Franco","Madrid, Eva","Izcovich, Ariel","32255438"],"abstract":["Introduction: The evidence on COVID-19 is being produced at high speed, so it is challenging for decision-makers to keep up. It seems appropriate, then, to put into practice a novel approach able to provide the scientific community and other interested parties with quality evidence that is actionable, and rapidly and efficiently produced. Methods and analysis: We designed a protocol for multiple parallel systematic reviews and overviews of systematic reviews in line with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses Protocols (PRISMA-P). We will search for primary studies and systematic reviews that answer different questions related to COVID-19 using both a centralized repository (Epistemonikos database) and a manual search in MEDLINE/PubMed, EMBASE, and the Cochrane Central Register of Controlled Trials. We will also search for literature in several other sources. At least two researchers will independently undertake the selection of studies, data extraction, and assessment of the quality of the included studies. We will synthesize data for each question using meta-analysis, when possible, and we will prepare Summary of Findings tables according to the GRADE approach. All the evidence will be organized in an open platform (L.OVE - Living OVerview of Evidence) that will be continuously updated using artificial intelligence and a broad network of experts. Ethics and dissemination: No ethics approval is considered necessary. The results of these articles will be widely disseminated via peer-reviewed publications, social networks, and traditional media, and will be sent to relevant international organizations discussing this topic."],"journal":"Medwave","authors":["Rada, Gabriel","Verdugo-Paiva, Francisca","Avila, Camila","Morel-Marambio, Macarena","Bravo-Jeria, Rocio","Pesce, Franco","Madrid, Eva","Izcovich, Ariel"],"date":"2020-04-08T11:00:00Z","year":2020,"_id":"32255438","source":"PubMed","week":"202015|Apr 06 - Apr 12","doi":"10.5867/medwave.2020.03.7867","keywords":["coronavirus infections","systematic review","covid-19"],"weight":0,"_version_":1666138493185687552,"score":72.969574},{"pmid":32377571,"pmcid":"PMC7199819","title":"eClinic: increasing use of telehealth as a risk reduction strategy during the covid-19 pandemic.","text":["eClinic: increasing use of telehealth as a risk reduction strategy during the covid-19 pandemic.","Prior to the covid-19 pandemic, telehealth was already being rapidly adopted nationally by healthcare systems. During the covid-19 pandemic, increased use of telehealth may be considered as a risk reduction strategy. Benefits of this strategy may be conferred to both patients and health providers.","Trauma Surg Acute Care Open","Kemp, Michael T","Williams, Aaron M","Alam, Hasan B","32377571"],"abstract":["Prior to the covid-19 pandemic, telehealth was already being rapidly adopted nationally by healthcare systems. During the covid-19 pandemic, increased use of telehealth may be considered as a risk reduction strategy. Benefits of this strategy may be conferred to both patients and health providers."],"journal":"Trauma Surg Acute Care Open","authors":["Kemp, Michael T","Williams, Aaron M","Alam, Hasan B"],"date":"2020-05-08T11:00:00Z","year":2020,"_id":"32377571","source":"PubMed","week":"202019|May 04 - May 10","doi":"10.1136/tsaco-2020-000481","keywords":["delivery of health care","health care quality, access, and evaluation","infections"],"topics":["Prevention"],"weight":1,"_version_":1666597097403580417,"score":72.53826}]}